{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:40:18Z","timestamp":1769017218344,"version":"3.49.0"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.2169\/internalmedicine.5004-20","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T22:07:43Z","timestamp":1603231663000},"page":"709-718","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study"],"prefix":"10.2169","volume":"60","author":[{"given":"Junya","family":"Makiyama","sequence":"first","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Japan"},{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machiko","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Japan"},{"name":"Department of Hematology, Nagasaki University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Chiwata","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Japan"},{"name":"Department of Hematology, Nagasaki University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kitanosono","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital, Japan"},{"name":"Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lymphoma Study Group of Japanese Pathologists. The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 50: 696-702, 2000.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-1484, 1992.","DOI":"10.1056\/NEJM199211193272102"},{"key":"3","unstructured":"3. Stein H, Pileri SA, Weiss LM, Proppema S, Gascoyne RD, Jaffe ES. Hodgkin lymphomas: Introduction. In: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al., Eds. IARC, Lyon, 2017: 424-430."},{"key":"4","unstructured":"4. Stark GL, Wood KM, Jack F, et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 119: 432-440, 2002."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Halbsguth TV, Boll B, Borchmann P, Diehl V. The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 6: 164-171, 2011.","DOI":"10.1007\/s11899-011-0089-7"},{"key":"6","unstructured":"6. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 71: 222-232, 2009."},{"key":"7","unstructured":"7. Sjoberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood 119: 990-996, 2012."},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119: 692-695, 2012.","DOI":"10.1182\/blood-2011-09-378414"},{"key":"9","unstructured":"9. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23: 5052-5060, 2005."},{"key":"10","unstructured":"10. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161: 76-86, 2013."},{"key":"11","unstructured":"11. Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20: 1087-1093, 2002."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Roy P, Vaughan Hudson G, Vaughan Hudson B, Esteve J, Swerdlow AJ. Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. Eur J Cancer 36: 384-389, 2000.","DOI":"10.1016\/S0959-8049(99)00267-1"},{"key":"13","unstructured":"13. Ropetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1: 18-24, 2003."},{"key":"14","unstructured":"14. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21: 3601-3608, 2003."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 8: 1935-1937, 1990.","DOI":"10.1200\/JCO.1990.8.12.1935"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244-1253, 1999.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"18","unstructured":"18. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24: 3128-3135, 2006."},{"key":"19","unstructured":"19. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339: 1506-1514, 1998."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Longo DL, Young RC, Hubbard SM, et al. Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med 100: 651-656, 1984.","DOI":"10.7326\/0003-4819-100-5-651"},{"key":"21","unstructured":"21. Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer 112: 1575-1584, 2015."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Makita S, Maruyama D, Maeshima AM, et al. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol 104: 236-244, 2016.","DOI":"10.1007\/s12185-016-2007-1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 31: 1522-1529, 2013.","DOI":"10.1200\/JCO.2012.45.4181"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 119: 6005-6015, 2012.","DOI":"10.1182\/blood-2011-12-396556"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Halbsguth TV, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 116: 2026-2032, 2010.","DOI":"10.1182\/blood-2009-11-253211"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.. Blood 118: 6292-6298, 2011.","DOI":"10.1182\/blood-2011-07-368167"},{"key":"27","unstructured":"27. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 170: 179-184, 2015."},{"key":"28","unstructured":"28. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer  41: 1051-1057, 2005."},{"key":"29","unstructured":"29. Nagai H. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-10. Hodgkin lymphoma (HL). Int J Hematol 111: 166-179, 2020."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/5\/60_5004-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T04:00:14Z","timestamp":1615003214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/5\/60_5004-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5004-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}